Senomyx (SNMX) Tumbles on Results, PepsiCo’s (PEP) Decision; Robotic-System’s FDA-Clearance Boosts Corindus Vascular (CVRS)


Senomyx Inc. (Nasdaq:SNMX) shares slumped more than 30% to touch a new 52-week low in the extended session Thursday after the company delivered a decrease in revenues and a small increase in losses in its quarterly financial results and said that it was notified – a couple days ago – by PepsiCo, Inc. (NYSE:PEP) that the food and beverage giant company is not going forward with the nationally launch of the reformulated version of Mug Root Beer containing Senomyx’s Sweetmyx S617

For the third quarter 2016, Senomyx posted revenues of $6.02 million, down from $7.39 million in the same period the prior year, and a net loss of ($2.46) million, or ($0.05) per diluted share versus a net loss of ($2.41) million, or ($0.05) per diluted share in the third quarter 2015. However, these results are better than the Capital IQ Consensus Estimate of ($0.07) loss per share on revenues of $5.88 million for the period

SNMX stock closed at $2.65, down $0.08 (or -2.93%), and 760,840 of its shares changed hands during the day, representing a large increase in activity verus its average volume (3m) of 329,356

Senomyx, which discovers, develops, and commercializes flavor ingredients for the packaged food, beverage, and ingredient supply industries, has 44.76M Shares Outstanding. At close on Thursday, the company had a Market Capitalization of $118.62M and SNMX stock one-year range was between $2.11 and $5.65 per share



Shares of Corindus Vascular Robotics, Inc. (NYSEMKT:CVRS) soared over 20% in after-hours trading Thursday as the company said that it has been given the green light – 510(k) clearance – by the U.S. Food and Drug Administration (FDA) to market its CorPath GRX, a medical device that brings robotic-precision during percutaneous coronary interventions

CVRS stock closed the regular session in negative territory by 3.89% (or -$0.038) at $0.942 with a total volume of 132,937 shares traded

Corindus Vascular Robotics, which designs, manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures, has 118.94M Shares Outstanding, Market Capitalization (intraday) of $112.03M and CVRS stock 52-week range is from $0.73 to $3.50 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at